Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.

Article  Google Scholar 

Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807–17.

Article  Google Scholar 

Garske-Román U, Sandström M, Fröss Baron K, et al. Prospective observational study of (177)Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970–88.

Article  Google Scholar 

Del Prete M, Buteau FA, Arsenault F, et al. Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46(3):728–42.

Article  Google Scholar 

Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22(3):406–16.

Google Scholar 

Li T, Ao ECI, Lambert B, Brans B, Vandenberghe S, Mok GSP. Quantitative imaging for targeted radionuclide therapy dosimetry - technical review. Theranostics. 2017;7(18):4551–65.

Article  Google Scholar 

Forrer F, Krenning EP, Kooij PP, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138–46.

Article  Google Scholar 

Svensson J, Rydén T, Hagmarker L, Hemmingsson J, Wängberg B, Bernhardt P. A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Phys. 2016;3(1): 21.

Article  Google Scholar 

Warfvinge CF, Gustafsson J, Roth D, et al. Relationship between absorbed dose and response in neuroendocrine tumors treated with [(177)Lu]Lu-DOTATATE. J Nucl Med. 2024;65(7):1070–5.

Article  Google Scholar 

Mileva M, Marin G, Levillain H, et al. Prediction of (177)Lu-DOTATATE PRRT outcome using multimodality imaging in patients with gastroenteropancreatic neuroendocrine tumors: results from a prospective phase II LUMEN study. J Nucl Med. 2024;65(2):236–44.

Article  Google Scholar 

Ljungberg M, Sjögreen Gleisner K. Personalized dosimetry for radionuclide therapy using molecular imaging tools. Biomedicines. 2016;4(4):25.

Article  Google Scholar 

Miwa K, Kakino R, Sato T, et al. Feasibility of individual dosimetry using RT-PHITS for patients with SPECT/CT imaging after (177)Lu-DOTATATE peptide receptor radionuclide therapy. Phys Eng Sci Med. 2025;48(2):949–57.

Article  Google Scholar 

O’Donoghue J, Zanzonico P, Humm J, Kesner A. Dosimetry in radiopharmaceutical therapy. J Nucl Med. 2022;63(10):1467–74.

Article  Google Scholar 

Garkavij M, Nickel M, Sjögreen-Gleisner K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116(4 Suppl):1084–92.

Article  Google Scholar 

Sundlöv A, Gustafsson J, Brolin G, et al. Feasibility of simplifying renal dosimetry in (177)Lu peptide receptor radionuclide therapy. EJNMMI Phys. 2018;5(1): 12.

Article  Google Scholar 

Handayani W, Chantadisai M, Phromphao B, Noipinit N, Pasawang P, Khamwan K. Comparative post-therapeutic dosimetry between 2D planar-based and hybrid-based methods for personalized Lu-177 treatment. Ann Nucl Med. 2024;38(11):884–93.

Article  Google Scholar 

Dewaraja YK, Frey EC, Sgouros G, et al. MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53(8):1310–25.

Article  Google Scholar 

Carter LM, Ocampo Ramos JC, Schuerrle SB, et al. MIRD pamphlet no. 30: MIRDfit-a tool for fitting of biodistribution time-activity data for internal dosimetry. J Nucl Med. 2024;65(11):1808–14.

Article  Google Scholar 

Uribe C, Peterson A, Van B, et al. An international study of factors affecting variability of dosimetry calculations, part 1: design and early results of the SNMMI dosimetry challenge. J Nucl Med. 2021;62(Suppl 3):36s–47s.

Article  Google Scholar 

Brosch-Lenz J, Ke S, Wang H, et al. An international study of factors affecting variability of dosimetry calculations, Part 2: overall variabilities in absorbed dose. J Nucl Med. 2023;64(7):1109–16.

Article  Google Scholar 

Miyaji N, Miwa K, Tokiwa A, et al. Phantom and clinical evaluation of bone SPECT/CT image reconstruction with xSPECT algorithm. EJNMMI Res. 2020;10(1):71.

Article  Google Scholar 

Miwa K, Nemoto R, Masuko H, et al. Evaluation of quantitative accuracy among different scatter corrections for quantitative bone SPECT/CT imaging. PLoS One. 2022;17(6): e0269542.

Article  Google Scholar 

Tran-Gia J, Lassmann M. Characterization of noise and resolution for quantitative (177)Lu SPECT/CT with xSPECT quant. J Nucl Med. 2019;60(1):50–9.

Article  Google Scholar 

Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med. 2009;50(3):477-84.

Khamwan K, O’Reilly SE, Plyku D, et al. Re-evaluation of pediatric 18F-FDG dosimetry: Cristy-Eckerman versus UF/NCI hybrid computational phantoms. Phys Med Biol. 2018;63(16):165012.

Chatachot K, Shiratori S, Chaiwatanarat T, Khamwan K. Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand. Ann Nucl Med. 2021;35(11):1193–202.

Hippeläinen E, Tenhunen M, Sohlberg A. Fast voxel-level dosimetry for (177)Lu labelled peptide treatments. Phys Med Biol. 2015;60(17):6685–700.

Article  Google Scholar 

Hippeläinen ET, Tenhunen MJ, Mäenpää HO, Heikkonen JJ, Sohlberg AO. Dosimetry software Hermes Internal Radiation Dosimetry: from quantitative image reconstruction to voxel-level absorbed dose distribution. Nucl Med Commun. 2017;38(5):357–65.

Article  Google Scholar 

Lim SM, DeNardo GL, DeNardo DA, et al. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med. 1997;38(9):1374–8.

Google Scholar 

Masaki Y, Yamashita Y, Isoda T, Kato T, Baba S. A study of differences in absorbed dose estimates by images used in dosimetry of Lu-177-DOTATATE therapy. Radiol Phys Technol. 2025;18:477–83.

Article  Google Scholar 

Ardenfors O, Nilsson JN, Thor D, Hindorf C. Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy. EJNMMI Phys. 2022;9(1): 44.

Article  Google Scholar 

Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with (177)Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59(1):75–81.

Article  Google Scholar